AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BIOME AUSTRALIA LTD

0.275

+0.0051.85%

Volume:59.40K

Turnover:16.04K

Market Cap:62.42M

PE:65.48

High:0.275

Open:0.270

Low:0.267

Close:0.270

52wk High:0.560

52wk Low:0.200

Shares:227.00M

Float Shares:121.51M

Volume Ratio:0.38

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.004

EPS(LYR):0.001

ROE:18.09%

ROA:3.02%

PB:10.30

PE(LYR):280.04

Loading ...

Overview Company News Filings

Is Now The Time To Look At Buying Biome Australia Limited (ASX:BIO)?

Simply Wall St.

Biome Australia Adds Greece Site to Lactiplantibacillus Plantarum Clinical Trial, Shares Jump 4%

MT Newswires Live

How Investors May Respond To Bio-Rad Laboratories (BIO) Facing Elliott’s Activist Push Over Sartorius Stake

Simply Wall St.

How Investors Are Reacting To Bio-Rad Laboratories (BIO) As RBC Sees Margin Upside Under New Leadership

Simply Wall St.

Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says

MT Newswires Live

Biome Australia Extends Supply Deal With Probiotical Through 2028

MT Newswires Live

Biome Australia Ltd-Probiotical Exclusive Supply Agreement Extended

THOMSON REUTERS

BRIEF-Biome Australia Says Co Continues To Expect FY26 To Be Profitable

Biome Australia Ltd - Continues to Expect FY26 to Be Profitable

THOMSON REUTERS

Assessing Bio-Rad Laboratories (BIO) Valuation After Citi Downgrade And China Diagnostics Concerns

Simply Wall St.

$1.56 Million Whale Re-Activates With SHIB and PEPE, XRP Stages $25 Million Comeback to Snap ETF Losing Streak, Binance Drafts 7 New AI, Gold and DeFi Pairs - Morning Crypto Report

BRIEF-Biome Australia Files Patent Application For Probiotic Strain BMB18

Biome Australia Ltd - Files Patent Application for Next Generation Probiotic Strain Bmb18

THOMSON REUTERS

Biome Australia Ltd-Change of Auditor

THOMSON REUTERS

The Bull Case For Bio-Rad Laboratories (BIO) Could Change Following Citigroup’s Downgrade To Neutral

Simply Wall St.

Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375

MT Newswires Live

BUZZ-Biome Australia rises on record half-year profit

UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BIO.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BIO.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BIO.AU\",,,,,undefined,":{"symbol":"BIO.AU","market":"AU","secType":"STK","nameCN":"BIOME AUSTRALIA LTD","latestPrice":0.275,"timestamp":1787551920000,"preClose":0.27,"halted":0,"volume":59400,"delay":0,"changeRate":0.018518518518518535,"nameEN":"BIOME AUSTRALIA LTD","floatShares":121511476,"shares":226998033,"eps":0.0042,"marketStatus":"Closed","change":0.005,"latestTime":"08-24 16:12:00 AEST","open":0.27,"high":0.275,"low":0.267,"amount":16037,"amplitude":0.02963,"askPrice":0.27,"askSize":8380,"bidPrice":0.265,"bidSize":21802,"shortable":3,"etf":0,"ttmEps":0.0042,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.27,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0.381836,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BIO.AU","preClose":0.27,"auctionPrice":0.27,"auctionVolume":472,"auctionTime":1787551242943,"referencePrice":0.275,"referenceTime":1787553720474,"auction":3,"marketStatus":"盘后竞价","timestamp":1787551242943}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BIO.AU\",,,,,undefined,":{"symbol":"BIO.AU","floatShares":121511476,"roa":"3.02%","roe":"18.09%","lyrEps":0.000982,"volumeRatio":0.381836,"shares":226998033,"dividePrice":0,"high":0.275,"amplitude":0.02963,"preClose":0.27,"low":0.267,"week52Low":0.2,"pbRate":"10.30","psRate":"2.84","week52High":0.56,"institutionHeld":0,"latestPrice":0.275,"committee":0.444702,"eps":0.0042,"divideRate":0,"volume":59400,"delay":0,"ttmEps":0.0042,"open":0.27,"prevYearClose":0.42,"prevWeekClose":0.27,"prevMonthClose":0.28,"prevQuarterClose":0.265,"fiveDayClose":0.27,"twentyDayClose":0.27,"sixtyDayClose":0.232},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIO.AU\",params:#limit:5,,,undefined,":[{"date":"2026-07-29","symbol":"BIO.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1785283200000,"name":null,"time":"Pre-MKt","dateTimestamp":1785247200000,"actualEps":null},{"date":"2026-02-22","symbol":"BIO.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2024-02-27","symbol":"BIO.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708988400000,"name":null,"time":"","dateTimestamp":1708952400000,"actualEps":null},{"date":"2024-01-30","symbol":"BIO.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1706569200000,"name":null,"time":"","dateTimestamp":1706533200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIO.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIO.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640989371","title":"Is Now The Time To Look At Buying Biome Australia Limited (ASX:BIO)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989371","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989371?lang=en_us&edition=fundamental","pubTime":"2026-06-01 06:03","pubTimestamp":1780264981,"startTime":"0","endTime":"0","summary":"Biome Australia Limited ( ASX:BIO ), might not be a large cap stock, but it received a lot of attention from a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/household/asx-bio/biome-australia-shares/news/is-now-the-time-to-look-at-buying-biome-australia-limited-as","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/household/asx-bio/biome-australia-shares/news/is-now-the-time-to-look-at-buying-biome-australia-limited-as","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7111","GIVE.AU","BK4585","IOZ.AU","BEAR.AU","XJO.AU","BK4121","QRE.AU","XKO.AU","SLF.AU","BBOZ.AU","E200.AU","VAS.AU","BK4588","IMLC.AU","GEAR.AU","LU1169589451.USD","VAP.AU","STW.AU","OZF.AU","IISV.AU","EIGA.AU","XAO.AU","OZR.AU","BIO.AU","IIGF.AU","BIO","QFN.AU","DACE.AU","ZYAU.AU","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638957393","title":"Biome Australia Adds Greece Site to Lactiplantibacillus Plantarum Clinical Trial, Shares Jump 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638957393","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638957393?lang=en_us&edition=fundamental","pubTime":"2026-05-27 11:50","pubTimestamp":1779853802,"startTime":"0","endTime":"0","summary":"Biome Australia (ASX:BIO) said the multi-center clinical trial of its first wholly proprietary strain, BMB18, or Lactiplantibacillus plantarum, was expanded from a single-centre study at La Trobe Univ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OZF.AU","GEAR.AU","BBOZ.AU","IMLC.AU","STW.AU","E200.AU","IIGF.AU","QFN.AU","VAP.AU","VAS.AU","ZYAU.AU","BK7111","XAO.AU","BEAR.AU","XKO.AU","IOZ.AU","QRE.AU","XJO.AU","IISV.AU","BIO.AU","OZR.AU","GIVE.AU","EIGA.AU","DACE.AU","SLF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638262560","title":"How Investors May Respond To Bio-Rad Laboratories (BIO) Facing Elliott’s Activist Push Over Sartorius Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2638262560","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638262560?lang=en_us&edition=fundamental","pubTime":"2026-05-26 12:38","pubTimestamp":1779770326,"startTime":"0","endTime":"0","summary":"On May 18, 2026, Elliott Investment Management disclosed a significant stake in Bio-Rad Laboratories and began pressing the company to address what it describes as prolonged share price underperformance since late 2021.\nA central focus of Elliott’s campaign is Bio-Rad’s multibillion-dollar ownership stake in Sartorius, which it argues could be used more effectively to enhance shareholder value.\nWe’ll now look at how Elliott’s activist involvement, particularly around Bio-Rad’s Sartorius...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/how-investors-may-respond-to-bio-rad-laboratories-bio-facing","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/how-investors-may-respond-to-bio-rad-laboratories-bio-facing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7111","ISBC","BIO","BK4121","BK4585","LU1169589451.USD","BK4211","BIO.AU","LU1169590202.USD","BK4588","BIO.B"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636751028","title":"How Investors Are Reacting To Bio-Rad Laboratories (BIO) As RBC Sees Margin Upside Under New Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2636751028","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636751028?lang=en_us&edition=fundamental","pubTime":"2026-05-18 15:26","pubTimestamp":1779089203,"startTime":"0","endTime":"0","summary":"Earlier this week, RBC Capital resumed coverage of Bio-Rad Laboratories, assigning an Outperform rating and emphasizing expectations for improved margins under new leadership and a recovery from product-specific challenges anticipated in 2026.\nRBC’s focus on a 2027 sales rebound and structurally stronger profitability highlights how management execution and product mix could reshape Bio-Rad’s longer-term outlook.\nNow, we’ll examine how RBC’s renewed confidence in Bio-Rad’s margin improvement...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/how-investors-are-reacting-to-bio-rad-laboratories-bio-as-rb","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/how-investors-are-reacting-to-bio-rad-laboratories-bio-as-rb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LU1169590202.USD","BIO","BK4211","BK7111","ISBC","BIO.B","LU1169589451.USD","BIO.AU","BK4585","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635116035","title":"Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2635116035","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635116035?lang=en_us&edition=fundamental","pubTime":"2026-05-15 23:30","pubTimestamp":1778859044,"startTime":"0","endTime":"0","summary":"Bio-Rad Laboratories'  sales growth should recover in 2027 following idiosyncratic product headwinds, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's new management will make efforts to structurally improve its margin profile.RBC said that some of the challenges Bio-Rad faces are company-specific, noting, for instance, that demand for Bio-Rad's process chromatography products is negatively impacted this year by the US Center for Disease Control's revisions of the childhood and adolescent immunization schedule.Analysts said that the company's near-term earnings before interest and taxes, or EBIT, margin growth target in the mid-teens, up from the 11% guidance for 2026, strongly signals meaningful restructuring ahead.RBC resumed coverage on the stock with an outperform rating and a $320 price target.Price: 248.61, Change: +2.34, Percent Change: +0.95","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4121","BIO","LU1169589451.USD","BK7111","BIO.AU","LU1169590202.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634259685","title":"Biome Australia Extends Supply Deal With Probiotical Through 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2634259685","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634259685?lang=en_us&edition=fundamental","pubTime":"2026-05-12 07:51","pubTimestamp":1778543473,"startTime":"0","endTime":"0","summary":"Biome Australia  has extended its exclusive supply agreement with partner Probiotical by two years through 2028, according to a Tuesday filing with the Australian bourse.The agreement was due to expire in June and was extended on existing commercial terms, per the filing.The extension comes as Biome looks to scale its presence across Australia, Canada, the UK, Ireland, and New Zealand.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7111","XKO.AU","BIO.AU","XAO.AU","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634731255","title":"Biome Australia Ltd-Probiotical Exclusive Supply Agreement Extended","url":"https://stock-news.laohu8.com/highlight/detail?id=2634731255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634731255?lang=en_us&edition=fundamental","pubTime":"2026-05-12 06:37","pubTimestamp":1778539079,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUE9PTM2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7111","BIO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630734220","title":"BRIEF-Biome Australia Says Co Continues To Expect FY26 To Be Profitable","url":"https://stock-news.laohu8.com/highlight/detail?id=2630734220","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630734220?lang=en_us&edition=fundamental","pubTime":"2026-04-28 09:31","pubTimestamp":1777339901,"startTime":"0","endTime":"0","summary":"BRIEF-Biome Australia Says Co Continues To Expect FY26 To Be ProfitableApril 28 (Reuters) - Biome Australia Ltd BIO.AX:CONTINUES TO EXPECT FY26 TO BE PROFITABLEFurther company coverage: BIO.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41A1BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIO.AU","BK7111"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630234619","title":"Biome Australia Ltd - Continues to Expect FY26 to Be Profitable","url":"https://stock-news.laohu8.com/highlight/detail?id=2630234619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630234619?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:15","pubTimestamp":1777331750,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41A1BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7111","BIO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630105354","title":"Assessing Bio-Rad Laboratories (BIO) Valuation After Citi Downgrade And China Diagnostics Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2630105354","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630105354?lang=en_us&edition=fundamental","pubTime":"2026-04-27 12:26","pubTimestamp":1777263980,"startTime":"0","endTime":"0","summary":"Citi downgrade puts Bio-Rad Laboratories (BIO) under closer scrutiny\nCitigroup’s move to cut Bio-Rad Laboratories (BIO) to Neutral and lower its outlook on the stock has refocused attention on the company’s process chromatography margins and diagnostics exposure to China.\nSee our latest analysis for Bio-Rad Laboratories.\nBio-Rad’s 8.46% one-month share price return contrasts with a 5.71% year-to-date share price decline. The one-year total shareholder return of 19.85% also sits against a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/assessing-bio-rad-laboratories-bio-valuation-after-citi-down","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/assessing-bio-rad-laboratories-bio-valuation-after-citi-down","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BIO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630757493","title":"$1.56 Million Whale Re-Activates With SHIB and PEPE, XRP Stages $25 Million Comeback to Snap ETF Losing Streak, Binance Drafts 7 New AI, Gold and DeFi Pairs - Morning Crypto Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630757493","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630757493?lang=en_us&edition=fundamental","pubTime":"2026-04-27 12:03","pubTimestamp":1777262580,"startTime":"0","endTime":"0","summary":"TL;DRWhale consolidation: A major investor moved$1.56 million into SHIB (55%) and PEPE (45%), signaling a \"sleeping capital\" reactivation in high-liquidity meme assets.XRP institutional pivot:XRP brok","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/156-million-whale-re-activates-with-shib-and-pepe-xrp-stages-25-million-comeback-to-snap-etf-losing","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/156-million-whale-re-activates-with-shib-and-pepe-xrp-stages-25-million-comeback-to-snap-etf-losing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["FDN","BK7111","XXRP","BK4585","AGIX","BIO","BK4550","BK4077","BK4121","TOXR","XRPT","CHAT","SOCL","ARTY","BK4508","BK4588","AIPO","BIO.AU","BK4551","XRPI","LU1169589451.USD","BITW","XRPZ","UXRP","SNAG","BK4576","XRPC","XRP","LU1169590202.USD","BK4554"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630358528","title":"BRIEF-Biome Australia Files Patent Application For Probiotic Strain BMB18","url":"https://stock-news.laohu8.com/highlight/detail?id=2630358528","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630358528?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:35","pubTimestamp":1777253713,"startTime":"0","endTime":"0","summary":"BRIEF-Biome Australia Files Patent Application For Probiotic Strain BMB18April 27 (Reuters) - Biome Australia Ltd BIO.AX:FILES PATENT APPLICATION FOR NEXT GENERATION PROBIOTIC STRAIN BMB18Further company coverage: BIO.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN4171F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7111","BIO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630334510","title":"Biome Australia Ltd - Files Patent Application for Next Generation Probiotic Strain Bmb18","url":"https://stock-news.laohu8.com/highlight/detail?id=2630334510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630334510?lang=en_us&edition=fundamental","pubTime":"2026-04-27 07:02","pubTimestamp":1777244541,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nFWN4171F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7111","BIO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626616287","title":"Biome Australia Ltd-Change of Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2626616287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626616287?lang=en_us&edition=fundamental","pubTime":"2026-04-10 15:11","pubTimestamp":1775805090,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nTUE4CD4HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIO.AU","BK7111"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626280976","title":"The Bull Case For Bio-Rad Laboratories (BIO) Could Change Following Citigroup’s Downgrade To Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2626280976","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626280976?lang=en_us&edition=fundamental","pubTime":"2026-04-09 07:25","pubTimestamp":1775690741,"startTime":"0","endTime":"0","summary":"In early April 2026, Citigroup downgraded Bio-Rad Laboratories’ rating from “Buy” to “Neutral,” signaling a shift in analyst sentiment toward the life science and clinical diagnostics company. \nThis reassessment comes as Bio-Rad is cited among key players in the rapidly expanding single-cell omics market, where demand for advanced tools in cancer, immunology, and stem cell research is intensifying.\nWe’ll now examine how Citigroup’s downgrade, against a backdrop of growing single-cell omics...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/the-bull-case-for-bio-rad-laboratories-bio-could-change-foll","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/the-bull-case-for-bio-rad-laboratories-bio-could-change-foll","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BIO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625958937","title":"Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375","url":"https://stock-news.laohu8.com/highlight/detail?id=2625958937","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625958937?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:38","pubTimestamp":1775561939,"startTime":"0","endTime":"0","summary":"Bio-Rad Laboratories (BIO) has an average rating of overweight and mean price target of $333.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU1169590202.USD","BIO.B","BIO","LU1169589451.USD","BK7111","BK4121","BIO.AU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613051592","title":"BUZZ-Biome Australia rises on record half-year profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2613051592","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613051592?lang=en_us&edition=fundamental","pubTime":"2026-02-23 11:48","pubTimestamp":1771818523,"startTime":"0","endTime":"0","summary":"BUZZ-Biome Australia rises on record half-year profit** Biome Australia BIO.AX rises as much as 4.9% to A$0.425; marks biggest intraday pct jump since February 2** Biotherapeutics makers posts record HY net profit of A$1.18 million ** Revenues from ordinary activities jumps 39.9% y/y to A$12.4 million** YTD, BIO down 1.8%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL6N3ZJ04R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIO.AU","BK7111"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611187169","title":"UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2611187169","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611187169?lang=en_us&edition=fundamental","pubTime":"2026-02-14 00:12","pubTimestamp":1770999156,"startTime":"0","endTime":"0","summary":"Bio-Rad Laboratories (BIO) has an average rating of overweight and mean price target of $335, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK7111","LU1169589451.USD","LU1169590202.USD","BK4588","BK4121","BIO.AU","BIO","BIO.B"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}